Nuvectis Pharma (NVCT) News Today → America’s worst nightmare? (From Porter & Company) (Ad) Free NVCT Stock Alerts $6.35 -0.05 (-0.78%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 11:47 AM | marketbeat.comNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Acquires 2,000 SharesNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur acquired 2,000 shares of the business's stock in a transaction that occurred on Friday, May 10th. The stock was purchased at an average price of $6.40 per share, for a total transaction of $12,800.00. Following the acquisition, the chief executive officer now directly owns 3,244,484 shares in the company, valued at approximately $20,764,697.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.May 13 at 1:52 AM | americanbankingnews.comHC Wainwright Equities Analysts Lift Earnings Estimates for Nuvectis Pharma, Inc. (NASDAQ:NVCT)May 11 at 1:54 AM | americanbankingnews.comQ2 2024 Earnings Estimate for Nuvectis Pharma, Inc. (NASDAQ:NVCT) Issued By Roth CapitalMay 10 at 7:06 AM | marketbeat.comNuvectis Pharma, Inc. Expected to Post Q2 2024 Earnings of ($0.23) Per Share (NASDAQ:NVCT)Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Analysts at Roth Capital increased their Q2 2024 EPS estimates for shares of Nuvectis Pharma in a research report issued on Tuesday, May 7th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of ($0.23)May 10 at 6:04 AM | americanbankingnews.comNuvectis Pharma (NASDAQ:NVCT) Rating Reiterated by HC WainwrightMay 10 at 4:16 AM | americanbankingnews.comNuvectis Pharma, Inc. Forecasted to Post FY2028 Earnings of $3.90 Per Share (NASDAQ:NVCT)May 9, 2024 | marketbeat.comFY2028 EPS Estimates for Nuvectis Pharma, Inc. (NASDAQ:NVCT) Boosted by Roth CapitalNuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Research analysts at Roth Capital increased their FY2028 earnings estimates for Nuvectis Pharma in a research report issued to clients and investors on Tuesday, May 7th. Roth Capital analyst J. Aschoff now anticipates that the company will postMay 8, 2024 | markets.businessinsider.comStrong Buy Rating for Nuvectis Pharma on Robust Financials and Promising Oncology Drug TrialsMay 8, 2024 | marketbeat.comNuvectis Pharma (NASDAQ:NVCT) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $21.00 price objective on shares of Nuvectis Pharma in a report on Wednesday.May 8, 2024 | finance.yahoo.comNuvectis Pharma Inc Reports Q1 2024 Financial OutcomesMay 7, 2024 | investorplace.comNVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024April 17, 2024 | finance.yahoo.comIs Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?April 11, 2024 | marketbeat.comNuvectis Pharma, Inc. to Post Q1 2024 Earnings of ($0.39) Per Share, HC Wainwright Forecasts (NASDAQ:NVCT)Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 EPS estimates for shares of Nuvectis Pharma in a note issued to investors on Monday, April 8th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($0.39) pApril 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)April 8, 2024 | finanznachrichten.deNuvectis Pharma, Inc.: Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 8, 2024 | markets.businessinsider.comNuvectis Pharma: Data Confirms Robust Activity Of NXP900 - Quick FactsApril 8, 2024 | finance.yahoo.comNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 8, 2024 | globenewswire.comNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 2, 2024 | investorplace.com5 Healthcare Stocks to Buy for 2024March 21, 2024 | finance.yahoo.comInsider Buys Additional US$51k In Nuvectis Pharma StockMarch 20, 2024 | insidertrades.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Purchases 5,000 Shares of StockMarch 19, 2024 | marketbeat.comNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Purchases $51,450.00 in StockNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur purchased 5,000 shares of Nuvectis Pharma stock in a transaction on Monday, March 18th. The stock was bought at an average cost of $10.29 per share, with a total value of $51,450.00. Following the transaction, the chief executive officer now directly owns 3,242,484 shares of the company's stock, valued at $33,365,160.36. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.March 19, 2024 | globenewswire.comNuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research MeetingMarch 15, 2024 | msn.comNuvectis reports initial data from Phase Ib ovarian cancer trialMarch 15, 2024 | marketwatch.comNuvectis Pharma Shares Rise 11% After Positive Preliminary Data for Cancer TreatmentMarch 15, 2024 | globenewswire.comNuvectis Pharma to Present at the 36th Annual Roth ConferenceMarch 14, 2024 | marketbeat.comTrading was temporarily halted for "NVCT" at 09:03 AM with a stated reason of "LULD pause."March 14, 2024 | globenewswire.comNuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian CancerMarch 6, 2024 | marketbeat.comFY2027 EPS Estimates for Nuvectis Pharma, Inc. Decreased by Analyst (NASDAQ:NVCT)Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Roth Capital lowered their FY2027 earnings estimates for Nuvectis Pharma in a note issued to investors on Tuesday, March 5th. Roth Capital analyst J. Aschoff now forecasts that the company will earn $1.20 per share for the year, down from theirMarch 6, 2024 | investorplace.comNVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023March 5, 2024 | finance.yahoo.comNuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical ProgressFebruary 19, 2024 | finance.yahoo.comNuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have significant skin in the game with 67% ownershipFebruary 9, 2024 | morningstar.comNuvectis Pharma Inc NVCTFebruary 9, 2024 | finance.yahoo.comCorrection: Nuvectis Pharma Announces Participation at Upcoming Investor ConferencesJanuary 3, 2024 | finance.yahoo.comNuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2023 | finance.yahoo.comNuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in CholangiocarcinomaNovember 25, 2023 | finance.yahoo.comNuvectis Pharma Insiders Added US$3.75m Of Stock To Their HoldingsNovember 8, 2023 | msn.comNuvectis Pharma GAAP EPS of -$0.37November 8, 2023 | benzinga.comRecap: Nuvectis Pharma Q3 EarningsOctober 24, 2023 | finance.yahoo.comNuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial CancerOctober 16, 2023 | finance.yahoo.comWe Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth CarefullyOctober 16, 2023 | msn.comDown -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)September 25, 2023 | finance.yahoo.comNuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate PresentationSeptember 22, 2023 | marketbeat.comBaldwin Brothers LLC MA Sells 53,739 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT)Baldwin Brothers LLC MA lowered its position in Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) by 37.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 90,061 shares of the company's stock after selling 53,739 shares during the quarter. BaldwinSeptember 21, 2023 | finance.yahoo.comNuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900September 16, 2023 | msn.comHC Wainwright & Co. Reiterates Nuvectis Pharma (NVCT) Buy RecommendationSeptember 15, 2023 | marketbeat.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Sees Significant Drop in Short InterestNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) was the target of a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 173,000 shares, a drop of 36.6% from the August 15th total of 273,000 shares. Based on an average daily volume of 59,000 shares, the days-to-cover ratio is currently 2.9 days. Approximately 3.3% of the shares of the company are sold short.September 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Werewolf Therapeutics (HOWL)September 12, 2023 | finance.yahoo.comNuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical TrialSeptember 12, 2023 | finance.yahoo.comWith 67% ownership, insiders at Nuvectis Pharma, Inc. (NASDAQ:NVCT) are pretty optimistic and have been buying recently Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Does this chart look familiar? (Ad)Investors who understand when to get in — and when to get out… Can make a lot of money. Like in the chart, I showed you above… Get all the information here. NVCT Media Mentions By Week NVCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVCT News Sentiment▼1.050.58▲Average Medical News Sentiment NVCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVCT Articles This Week▼231▲NVCT Articles Average Week Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AMLX News KPTI News FGEN News SYRS News SGMT News VTGN News PDSB News DMAC News RPTX News ABEO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NVCT) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressProtect Your Bank Account Before It’s Too LateWeiss RatingsHow Biden has already won 2024Porter & CompanyUrgent Nvidia WarningAltimetryCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
